Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071187 | 0.94 | IDO1 (0.45) | L3MBTL1MAOASIGMAR1IDO1 | |
| SCHEMBL873038 | 0.85 | MMP12 (0.45) | — | |
| SCHEMBL8073064 | 0.81 | L3MBTL1 (0.44) | L3MBTL1MAOASIGMAR1MAOBIDO1 | |
| SCHEMBL6755988 | 0.79 | SIGMAR1 (0.46) | L3MBTL1SIGMAR1 | |
| SCHEMBL15929720 | 0.78 | TRPA1 (0.45) | L3MBTL1MAOAMAOB | |
| SCHEMBL21771946 | 0.77 | IDO1 (0.46) | L3MBTL1MAOASIGMAR1MAOBIDO1 | |
| SCHEMBL105419 | 0.77 | LMNA (0.53) | L3MBTL1MAOASIGMAR1MAOB | |
| SCHEMBL8921201 | 0.77 | L3MBTL1 (0.55) | L3MBTL1 | |
| SCHEMBL9223815 | 0.77 | L3MBTL1 (0.55) | L3MBTL1 | |
| SCHEMBL18943155 | 0.77 | L3MBTL1 (0.41) | L3MBTL1MAOASIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-6127426-A | ANTIALLERGIC AND -INFLAMMATORY AGENTS E.G., TREATING PSORIASIS, BLOCKED ON THE C-10 BY A NONPHENOLIC ARYLACYL OR A PHENYLALKYLIDENE GROUP; LIPOXYGENASE INHIBITORS; ANTIPROLIFERATIVE AGENTS; LOW DOSAGE; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-10-03 | — | — | US | disclosed |
| EP-0664780-B1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMA (IL) | 1999-12-08 | — | — | EP | disclosed |
| US-5952390-A | ANTIINFLAMMATORY AGENTS; TREATMENT FOR PSORIASIS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-09-14 | — | — | US | disclosed |
| US-5844004-A | 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceuticals | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-12-01 | — | — | US | disclosed |
| US-5661187-A | ADMINISTERING TO TREAT AN ALLERGIC OR INFLAMMATORY CONDITION; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-08-26 | — | — | US | disclosed |
| EP-0664780-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-02 | — | — | EP | disclosed |
| US-5426197-A | Antiinflammatory, antiallergy or antitumor agents | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-06-20 | — | — | US | disclosed |
| WO-1995003266-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | L3MBTL1 2681/4885MAOA 1693/4885SIGMAR1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.